Title
Pretreatment with the monoacylglycerol lipase inhibitor URB602 protects from the long-term consequences of neonatal hypoxic-ischemic brain injury in rats

Permalink
https://escholarship.org/uc/item/8bz4n0w2

Journal
Pediatric Research, 72(4)

ISSN
0031-3998

Authors
Carloni, S
Alonso-Alconada, D
Girelli, S
et al.

Publication Date
2012-10-01

DOI
10.1038/pr.2012.91

License
CC BY 4.0

Peer reviewed
Pretreatment with the monoacylglycerol lipase inhibitor URB602 protects from the long-term consequences of neonatal hypoxic–ischemic brain injury in rats

Silvia Carloni1, Daniel Alonso-Alconada2, Silvia Girelli1, Andrea Duranti3, Andrea Tontini3, Daniele Piomelli4,5, Enrique Hilario2, Antonia Alvarez2 and Walter Balduini1

**BACKGROUND:** The endocannabinoids are emerging as natural brain protective substances that exert potentially beneficial effects in several neurological disorders by virtue of their hypothermic, immunomodulatory, vascular, antioxidant, and antiapoptotic actions. This study was undertaken to assess whether preventing the deactivation of the endocannabinoid 2-arachidonoylglycerol (2-AG) with the monoacylglycerol lipase (MAGL) inhibitor URB602 can provide neuroprotective effects in hypoxia–ischemia (HI)-induced brain injury.

**METHODS:** URB602 was administered into the right lateral ventricle 30 min before 7-day-old pup rats were subjected to HI. The neuroprotective effect was evaluated on postnatal day (PN) 14 or at adulthood (PN80) using behavioral and histological analyses. Activated caspase–3 expression and propidium iodide labeling were assessed as indexes of apoptotic and necrotic cell death, respectively.

**RESULTS:** Pretreatment with URB602 reduced apoptotic and necrotic cell death, as well as the infarct volume measured at PN14. At adulthood, URB602-treated HI animals performed better at the T-maze and the Morris maze, and also showed a significant reduction of brain damage.

**CONCLUSION:** These results demonstrate that a pretreatment with URB602 significantly reduces brain damage and improves functional outcome, indicating that endocannabinoid-degrading enzymes may represent an important target for neuroprotection in neonatal ischemic brain injury.

In the past decades, important advances have been made in cannabinoid (CB) research, with the endocannabinoids emerging as natural brain protective substances. These are part of a new intercellular communication network, called the endocannabinoid system (1). The endocannabinoid system comprises the CB receptors (CB1, CB2, and non-CB1/CB2 receptors), the endocannabinoids N-arachidonylethanolamine (anandamide; AEA), 2-arachidonoylglycerol (2-AG), and the enzymes responsible for endocannabinoid biosynthesis, transport, and degradation (1).

Acting as retrograde messengers, endocannabinoids provide neuromodulatory functions in the brain, regulating processes such as motor activity, memory and learning, appetite, emesis, nociception, and the survival or death decision of neural cells after harmful insults (1,2). They exert potentially beneficial effects by virtue of their hypothermic, immunomodulatory, vascular, antioxidant, and antiapoptotic actions (3,4), which can generate a neuroprotective response after several neurological disorders.

Following an ischemic brain injury, there is an increased production and accumulation of endocannabinoids in the brain (5,6), and upregulation of CB receptors (7,8). Activation of the endocannabinoid system has been extensively evaluated as a possible target for the treatment of cerebral ischemia (7,9,10), trauma (11), and excitotoxicity (12,13). Enhanced levels of endocannabinoids have also been observed in the brain after an acute excitotoxic insult in newborn rats and exogenous administration of synthetic or endocannabinoids has shown neuroprotective effects both in vitro and in vivo (7,14,15).

After activation of CB receptors, endocannabinoids are rapidly inactivated by reuptake and enzymatic hydrolysis, therefore limiting their potential protective effects. Termination of endocannabinoid signaling is carried out primarily by fatty acid amide hydrolase, which degrades AEA, and monoacylglycerol lipase (MAGL), which hydrolyzes 2-AG (1). Because the effects of exogenous CB receptor agonists do not appear too specific (16), currently interest is gradually shifting to the alternative approach of amplifying the effects of endocannabinoids by preventing their deactivation. Indeed, an interesting aspect of endocannabinoid activity is the rapid induction of their synthesis, receptor activation, and degradation. On these bases, the endocannabinoid system has been suggested to act on demand, with a tightly regulated spatial and temporal selectivity (1). The system, therefore, exerts its modulatory actions only when and where it is needed and this fact poses an important distinction between the physiological functions of the...
endocannabinoid system and the pharmacological actions of exogenous CB receptor agonists, which lack such selectivity. Thus, by using “endocannabinoid enhancers” instead of exogenous CBs, it may be possible to avoid ubiquitous receptor activation, allowing the activation of the endocannabinoid system in a temporally and spatially restricted manner. This approach has been recently seen in rat organotypic hippocampal slices where a protective effect of the MAGL inhibitor URB602 was reported (17).

This study was undertaken to evaluate the potential in vivo neuroprotective properties of URB602 in neonatal hypoxic–ischemic brain injury.

RESULTS
URB602 Reduces the Brain Damage Induced by Neonatal HI
To assess the effect of MAGL inhibition on brain damage and find the dose to be used in long-term experiments, different groups of animals were treated with intracerebroventricular injection 30 min before hypoxia–ischemia (HI) with several doses of URB602. In these experiments, animals were euthanized and evaluated for histological damage 7 days after HI. Figure 1 shows a quantitative evaluation of the effect of the different treatments on brain damage. These experiments revealed a significant reduction of brain injury when URB602 was administered at doses of 12.5 µg.
and 25 µg (Figure 1a,b) into the right ventricle, ipsilateral to the occluded carotid, or when a dose of 50 µg was injected into the left ventricle, contralateral to the occluded carotid (Figure 1c). The percentage reduction of brain volume calculated for the whole hemisphere, the cerebral cortex and the hippocampus for vehicle-treated ischemic animals and ischemic animals treated with a dose of 25 µg URB602 were 48.9 vs. 35.8%, 61.8 vs. 42.2%, and 52.2 vs. 40.3%, respectively. These data indicate that administration of the MAGL inhibitor URB602 results in neuroprotection. The dose of 25 µg per rat was selected for evaluating the neuroprotective effect of URB602 in short-term biochemical studies and long-term behavioral studies.

Figure 2. Effects of neonatal hypoxia-ischemia (HI) and of treatment with URB602 on apoptotic and necrotic cell death. (a) Representative photomicrographs showing the expression of cleaved caspase-3 in the lesioned side of the cerebral cortex (top panels) and hippocampus (CA1 (middle panels) and CA2/CA3 (bottom panels)) of ischemic (HI) and URB602-treated ischemic animals (HI + URB602). (b) Representative western blots and quantitative evaluation of cleaved caspase-3 (p17) expression in ischemic (HI) and URB602-treated ischemic animals (HI + URB602) 24 h after HI. Data are expressed as optical density (OD) integration and are the mean ± SEM (n = 5/group). L, left side, contralateral; R, ipsilateral to occluded carotid artery; ‡, nondetectable, § P < 0.01; one-way ANOVA was followed by Newman–Keuls multiple comparison test. β-actin was run as an internal standard. (c) Photomicrographs showing cells labeled with propidium iodide (PI) and PI-positive cells counted in the lesioned side of the three hippocampus regions (CA1 (top panels), CA2/CA3 (middle panels) and dentate gyrus (DG) (bottom panels)) of ischemic (HI) and URB602-treated ischemic animals (HI + URB602). Data are reported as the mean ± SEM (n = 5/group). The green (caspase-3) and red (PI) colors were converted to grayscale. *P < 0.05 and §P < 0.01 as compared with the HI group; Mann–Whitney U test. Scale bars = 100 µm.
that the administration of URB602 reduces both apoptotic and necrotic cell death.

**URB602 Reduces HI-Induced Long-Lasting Behavioral Alterations and Brain Damage**

We next tested if URB602 administration could also improve the long-lasting behavioral alterations observed in this model of neonatal HI. URB602 treatment did not affect the animal growth rate, assessed as body weight at weaning (21d old: control 51.2 ± 1.0; URB602 53 ± 2.4; HI 49.3 ± 0.9; HI + URB602 54.8 ± 1.1 g; P > 0.05) and adulthood (80 d old: control 389.6 ± 12; URB602 393 ± 7.9; HI 402.2 ± 9.1; HI + URB602 409 ± 6.3 g; P > 0.05). When tested in the T-maze from postnatal day (PN) 28 to PN30, in agreement with our earlier studies (18–21), ischemic rats preferentially chose the arm ipsilateral to the damaged side (P < 0.01). The percentage of right/left choices of HI + URB602 animals, although higher, was not statistically different (Figure 3a).

Learning abilities were tested in a Morris maze using a training-to-criterion test from PN45 to PN57 (Figure 3b). Groups did not differ in the number of sessions required to find the submerged pedestal in the first position (P = 0.056). However, the HI group had significantly impaired performances compared with controls when the pedestal was placed in the second or in the third position (Figure 3b, P < 0.05). The URB602-treated ischemic group took slightly more than half the number of sessions needed by the ischemic group to reach the criterion (11 ± 2 vs. 19 ± 3, respectively). After 15 days, (PN72) animals were tested for retention (Figure 3c). In this test, only ischemic rats differed significantly from controls in the time required to find the submerged pedestal (P < 0.01). The URB602-treated ischemic group took a shorter time to find the pedestal as compared with the ischemic group (20.5 ± 3.6 vs. 33.5 ± 5.2 s, respectively). It should also be noted that URB602-treated control animals did not differ from the control group in both tests.

Animals were euthanized at the end of the behavioral tests (PN80) and evaluated for brain damage. A quantitative evaluation of brain damage at adulthood is reported in Figure 3d. No differences were observed between the whole-brain volume of control and URB602-treated animals. Adult ischemic animals, however, showed a marked degeneration of the hemisphere on the occluded side. No injury was evident on the left side of the forebrain, cerebellum, or brainstem. Brain damage was significantly reduced in URB602-treated ischemic animals (Figure 3d).

**DISCUSSION**

In this study we show that pretreatment with URB602 protects from brain damage in a neonatal model of HI. We also show that the neuroprotective effect of URB602 is long lasting, as both brain injury and behavioral outcomes were significantly improved when ischemic animals were assessed at adulthood.
Indeed, URB602-treated animals did not differ from controls in either the T-maze or the water maze, and this cognitive improvement correlated with a significant reduction of brain damage in the cerebral cortex and hippocampus, brain areas known to be essential for acquisition and retention of spatial memory tasks. Biochemical evidence indicates that URB602-induced reduction of brain injury was associated with decreased apoptotic pathway activation (reduced activation of caspase-3), and occurred without shifting to necrotic cell death (decreased number of propidium iodide–positive cells) (18).

A growing body of evidence indicates that CBs modulate pathways involved in numerous harmful events (3,4) and show neuroprotective effects in different paradigms of hypoxic–ischemic brain injury (7,14,22). It is well known that ischemic brain tissue produces and accumulates both 2-AG and AEA, whose protective role has been highlighted either by their exogenous administration or by the inhibition of their metabolic enzymes (9,10,15). Thus, it is not surprising to consider endocannabinoids as endogenous protective molecules and, by extension, the endocannabinoid system as a potential target for new drugs that could improve ischemic injury. However, the effects of exogenous CB receptor agonists do not appear to be very specific (16), and currently the interest is gradually shifting to the alternative approach of amplifying the effects of endocannabinoids by preventing their deactivation. Thus, by using these “endocannabinoid enhancers” instead of exogenous CBs, it may be possible to avoid ubiquitous receptor activation. MAGL is the main enzyme involved in 2-AG hydrolysis (23), and specific MAGL inhibitors could block 2-AG deactivation and therefore amplify its intrinsic actions. URB602 is known to increase 2-AG levels and enhance 2-AG-mediated signaling in neurons (24,25), without affecting the activities of other lipid-metabolizing enzymes such as fatty acid amide hydrolase (which hydrolyzes AEA), diacylglycerol lipase, or COX-2 (25,26). On these bases, URB602 is considered to be a selective inhibitor of MAGL activity that may therefore regulate the 2-AG-CB1 receptor signaling. URB602 also possess anti-inflammatory effects (27) that have been correlated to the protective effects of exogenous 2-AG, which lessen inflammation via reduction of nuclear factor-κB and COX-2 activation and cytokine and reactive oxygen species formation (11,28,29).

This study shows that URB602 is neuroprotective in a neonatal model of HI, but the mechanism(s) by which neuroprotection was achieved was not investigated. Our results are in accordance with those recently reported by Landucci et al. (17) showing that URB602 had protective effects in a model of ischemia in rat organotypic hippocampal slices. They also found that the effect of URB602 was comparable with that observed after exogenous 2-AG administration and that neuroprotection was blocked by the CB1 antagonist AM251. Furthermore, they reported that blocking the fatty acid amide hydrolase/AEA pathway with URB597 did not have protective effect, indicating that it is the amplification of the MAGL/2-AG pathway that might play a pivotal role in the neuroprotective effect of the endocannabinoid system (17). Accordingly, preliminary results obtained with the fatty acid amide hydrolase inhibitor URB597 (17,25) in our model of HI have shown that this compound does not have protective effects (data not shown). Taken together, this evidence makes us confident that the protective effect of URB602 observed after in vivo administration could be mediated by its effect on MAGL, although CB-independent effects of the compound cannot be excluded.

In conclusion, the results of this study indicate that treatment with URB602 is neuroprotective and has long-lasting beneficial effects on HI occurring during brain development. Even though further investigation is required to elucidate the underlying bases for its neuroprotective effect, the well-established effect of URB602 with the endocannabinoid degrading enzyme MAGL (24,25) supports the hypothesis that the approach of amplifying the effects of endocannabinoids by preventing their deactivation can offer a promising therapeutic approach for reducing ischemia-induced neurodegeneration in the neonate. Before these agents can be proposed for treating asphyxiated fetus or newborns, however, further studies must determine if they are effective when systemically administered after the ischemic insult and if they can present toxicity in the newborn.

METHODS

Animals
All surgical and experimental procedures were carried out in accordance with the Italian regulations for the care and use of laboratory animals, and were approved by the animal care committee of the University of Urbino “Carlo Bo.” Female Sprague–Dawley rats (Charles River, Milan, Italy) were housed with breeder males and conception determined by vaginal smear. Pregnant rats were then housed in individual cages and the day of delivery was considered day 0 for the pups. On PN1, litters of pups born on the same day were randomized and reduced to 10 male rats per litter. Each litter contained pups assigned to the different groups of treatment with the purpose of circumventing litter effects.

Cerebral HI
The procedure used was a slight modification of the one described by Rice et al. (30). Seven-day-old animals were anesthetized with 3% isoflurane in a N2O/O2 (70/30%) mixture and the right common carotid artery of each pup was exposed, isolated from nerve and vein, and ligated with surgical silk. The wound was then sutured and the animal allowed to recover for 3 h under a heating lamp. Pups were then placed in airtight jars and exposed for 2.5 h to a humidified nitrogen–oxygen mixture (92% and 8%, respectively) delivered at 5–6 l/min. The jars were partially submerged in a 37°C water bath to maintain a constant thermal environment. Rectal temperature was measured before surgery and at the end of the period of hypoxia. No differences were found among groups (data not shown).

Drug Synthesis and Administration
URB602 (biphenyl-3-ylcarbamic acid cyclohexyl ester; Figure 4) was synthesized as described earlier (31) or, alternatively, as follows.

To a solution of biphenyl-3-yl isocyanate (1 equivalent), obtained from the corresponding carboxylic acid, in cyclohexanol, CuX (X = Cl, Br) (0.5 equivalent) was added and the mixture stirred at 50°C overnight. The solvent was then evaporated. Purification of the residue by column chromatography (cyclohexane/ethyl acetate, 9:1) gave URB602 as a white solid. URB602 was administered by intracerebroventricular injection. Briefly, the pups were anesthetized and placed in a stereotaxic frame. Intracerebroventricular injections were made into the right lateral ventricle using a 5μ Hamilton syringe. Four microliters containing different doses of URB602 (dissolved in phosphate buffered saline (PBS) containing 52.5% dimethylsulfoxide) or the corresponding volume of vehicle was injected 30 min before HI.
Chemical structure of compound URB602.

Long-Lasting Behavioral Studies

Each experiment included the following groups (n = 10): (i) vehicle-treated control animals (control), (ii) URB602-treated control animals (URB602), (iii) vehicle-treated ischemic animals (HI), and (iv) URB602-treated ischemic animals (HI + URB602).

T-maze. The apparatus was a T-maze with 11-cm-wide floor and 18-cm-high walls. The stem of both arms was 40 cm long. Lighting was provided by a lamp suspended above the apparatus. The start arm contained a guillotine door. Spontaneous alternation refers to the tendency of the animal to enter opposite goal boxes in consecutive unrewarded trials in a T-maze. Starting on PN28, each animal was given three trials in the T-maze, giving a chance for two alternations, and the data recorded at 0%, 50%, or 100% alternation for each animal.

Morris maze. Animals were tested starting from PN45. In this task, animals must find a submerged pedestal located below the surface of water (white colored). Animals were evaluated in a training-to-criterion test. The test started by placing the animal in the water facing the wall of the pool in the opposite position of the one containing the pedestal. If the animal located and climbed onto the pedestal, it was permitted 30 s on the pedestal before the next trial started. If the animal did not find the pedestal within 120 s it was placed directly on the pedestal and allowed a 30-s rest period. The performance criterion was three trials in a row with an average time before escape of <20 s. When the animal reached the criterion, it was transferred to the next location the next day. Each animal received a maximum of 32 trials for each of the three positions of the pedestal. Data are expressed as the number of sessions needed to reach the criterion.

After 15 d (PN72), each rat was tested for eight additional trials with the pedestal placed in the third position. Each trial lasted 1 min and the time taken to find the platform was recorded. If the animal located and climbed onto the pedestal within the 1 min trial, it was permitted to stay 30 s on the pedestal before the next trial started. If the animal did not find the pedestal within 1 min it was placed directly on the pedestal and allowed a 30-s rest period. Data of the recall section are expressed as the total time taken to find the pedestal in the eight trials.

Assessment of Brain Injury

Brain injury was evaluated on PN14 or at the end of the long-term experiments (PN80). Animals were anesthetized, euthanized by decapitation, and the brains immediately frozen in dry ice. To evaluate tissue injury, coronal sections (40 µm thick) of the brain of each animal were cut on a cryostat and thaw-mounted onto acid-washed subbed slides (gelatin and chrome alum). Sections were then postfixed with 4% paraformaldehyde in 0.1 mol/l PBS. The tissue was then processed for antigen retrieval by immersing overnight in 10 mmol/l sodium citrate buffer (pH 6.0, 4°C) and boiling in the same buffer for 3 min. After boiling, brains were cryoprotected with 30% sucrose/PBS (72 h, 4°C). Brain sections (thickness 20 µm) were incubated with 1:500 normal blocking serum for 1 h at room temperature and then overnight at 4°C with anticleaved caspase-3 (1:50, polyclonal; Cell Signaling Technology, Danvers, MA). Fluorescein isothiocyanate-conjugated horseradish peroxidase–conjugated antirabbit antibody (1:4000) and detected using the ECL system (Amersham Pharmacia Biotech, Milan, Italy). A monoclonal antibody against β-actin (1:4000, Santa Cruz Biotechnology, Segrato, Italy) was used as control for protein gel loading. Blots were analyzed using the NIH Image software. Data were normalized to those of β-actin and expressed as optical density integration.

Biochemical and Immunohistochemical Analyses

These experiments were performed on separated groups of ischemic (n = 10) and URB602-treated ischemic (HI + URB602; n = 10) animals. Animals were killed for biochemical experiments 24 h after HI. In additional groups of HI (n = 5) and HI + URB602 rats (n = 5), propidium iodide (Sigma, Milan, Italy; P4170) dissolved in distilled water was injected at 0.5 µg/rat into the right lateral ventricle in a volume of 0.5 µl (7). Twenty minutes after injection, animals were killed and perfusion-fixed with 4% paraformaldehyde in 0.1 mol/l PBS.

Western blot analysis. This analysis was performed on ischemic and contralateral cortices of rats in the HI and HI + URB602 groups. Samples (50 µg protein; Bradford dye-binding procedure, BioRad Laboratories, Segrato, Italy) were separated onto SDS-polyacrylamide gels and probed with a cleaved caspase-3 antibody (1:1000, polyclonal; Cell Signaling Technology, Danvers, MA). Immunoblots were processed with horseradish peroxidase–conjugated antirabbit antibody (1:4000) and detected using the ECL system (Amersham Pharmacia Biotech, Milan, Italy). A monoclonal antibody against β-actin (1:4000, Santa Cruz Biotechnology, Segrato, Italy) was used as control for protein gel loading. Blots were analyzed using the NIH Image software. Data were normalized to those of β-actin and expressed as optical density integration.

Immunohistochemistry. Pups were deeply anesthetized and perfusion-fixed with 4% paraformaldehyde in 0.1 mol/l PBS. Brains were rapidly removed, placed on ice, and processed for antigen retrieval by immersing overnight in 10 mmol/l sodium citrate buffer (pH 6.0, 4°C) and boiling in the same buffer for 3 min. After boiling, brains were cryoprotected with 30% sucrose/PBS (72 h, 4°C). Brain sections (thickness 20 µm) were incubated with 1:500 normal blocking serum for 1 h at room temperature and then overnight at 4°C with anticleaved caspase-3 (1:50, polyclonal; Cell Signaling Technology, Danvers, MA). Fluorescein isothiocyanate-conjugated horse antirabbit IgG (1:200, Santa Cruz Biotechnology) was used to demonstrate immunoreactivity of cleaved caspase-3 as green fluorescence. The specificity of the reactions was evaluated in some slices by omitting the primary antibody from the incubation medium.

Cell counting. Cell counting was conducted in three different regions of the hippocampus on ×20 microscopic images using a BX-51 Olympus microscope. Positive cells were counted using the NIH Image software in three separate fields of each region of the hippocampus in slices cut at the level A 3750 of the Koning and Klippel stereotaxic atlas. Five animals in each group were analyzed.

Data Analysis

The Mann–Whitney U test was used to analyze left and right choices in the T-maze. Data from the training-to-criterion test in the Morris water maze were analyzed using the Kruskal–Wallis test followed by Dunn’s multiple comparison test and data from the retention test by one-way ANOVA followed by Newman–Keuls multiple comparison test. Whole-brain or regional volumes after injury were analyzed by Mann–Whitney U test or by one-way ANOVA followed by Newman–Keuls post hoc test. The relative intensities of the bands detected by western blot were analyzed using NIH Image 1.62 software and statistical analyses performed by one-way ANOVA; data are presented as mean ± SEM.

ACKNOWLEDGMENTS

We thank Claudia Scopa for the excellent technical assistance and Kevin Worrell for his helpful hints.

STATEMENT OF FINANCIAL SUPPORT

This work was supported by Italian MIUR (Ministero dell’Università e della Ricerca) and University of Urbino “Carlo Bo.”

REFERENCES